Renalytix Plc

DB:2O9 Stock Report

Market Cap: €47.1m

Renalytix Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:2O9 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Dec 24Buy€2,942Fergus FlemingIndividual25,000€0.12
10 Dec 24Buy€2,578James McCulloughIndividual25,000€0.10
10 Dec 24Buy€2,372Julian BainesIndividual23,000€0.10
10 Dec 24Buy€5,399Howard DoranIndividual50,000€0.11
09 Dec 24Buy€4,835Howard DoranIndividual50,000€0.097
05 Dec 24Buy€4,824James McCulloughIndividual53,300€0.091
05 Dec 24Buy€4,106Christopher MillsIndividual48,601€0.084
04 Dec 24Buy€2,100Julian BainesIndividual23,989€0.088
01 Nov 24Buy€1,429,291Mount Sinai School Of Medicine, Endowment ArmCompany13,366,750€0.11
07 Oct 24Sell€7,982Harwood Capital LLPCompany83,696€0.095
15 Aug 24Sell€8,637Polar Capital Holdings PlcCompany50,000€0.17
14 Aug 24Sell€4,237Polar Capital Holdings PlcCompany25,000€0.17
08 Aug 24Sell€4,791Polar Capital Holdings PlcCompany28,000€0.17
26 Jun 24Sell€52,741Heights Capital Management, Inc.Company350,000€0.15
25 Jun 24Sell€28,263Heights Capital Management, Inc.Company175,000€0.16
18 Jun 24Sell€20,379Heights Capital Management, Inc.Company100,000€0.20
14 Jun 24Sell€205,426Heights Capital Management, Inc.Company980,000€0.21
13 Jun 24Sell€38,637Heights Capital Management, Inc.Company200,000€0.19
12 Jun 24Sell€19,295Heights Capital Management, Inc.Company100,000€0.19
07 Jun 24Sell€14,082Heights Capital Management, Inc.Company72,500€0.19
06 Jun 24Sell€48,470Heights Capital Management, Inc.Company250,000€0.19
05 Jun 24Sell€19,388Heights Capital Management, Inc.Company100,000€0.19
04 Jun 24Sell€19,386Heights Capital Management, Inc.Company100,000€0.19
03 Jun 24Sell€63,192Heights Capital Management, Inc.Company325,000€0.19
31 May 24Sell€13,402Heights Capital Management, Inc.Company75,000€0.18
30 May 24Sell€4,847Heights Capital Management, Inc.Company25,000€0.19
29 May 24Sell€7,714Heights Capital Management, Inc.Company37,500€0.21
28 May 24Sell€5,287Heights Capital Management, Inc.Company25,000€0.21
22 May 24Sell€2,232Heights Capital Management, Inc.Company10,000€0.22
16 May 24Sell€26,812Heights Capital Management, Inc.Company100,000€0.27
15 May 24Sell€48,080Heights Capital Management, Inc.Company175,000€0.27
14 May 24Sell€2,850Heights Capital Management, Inc.Company10,000€0.28
09 May 24Sell€42,053Heights Capital Management, Inc.Company97,212€0.58
07 May 24Sell€12,567Heights Capital Management, Inc.Company40,000€0.31
06 May 24Sell€14,678Heights Capital Management, Inc.Company23,412€0.63
02 May 24Sell€55,186Heights Capital Management, Inc.Company175,000€0.32
01 May 24Sell€18,780Heights Capital Management, Inc.Company73,002€0.26
30 Apr 24Sell€43,385Heights Capital Management, Inc.Company166,998€0.26
29 Apr 24Sell€2,811Heights Capital Management, Inc.Company10,000€0.28
24 Apr 24Buy€2,189,859Mount Sinai School Of Medicine, Endowment ArmCompany9,360,374€0.23

Insider Trading Volume

Insider Buying: 2O9 insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 2O9?
Owner TypeNumber of SharesOwnership Percentage
Public Companies30,1160.00909%
Private Companies8,080,0862.44%
Hedge Funds17,946,2985.42%
General Public22,700,6106.85%
Individual Insiders52,057,01815.7%
VC/PE Firms52,406,04415.8%
Institutions177,985,84053.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 231.4%.

Top Shareholders

Top 25 shareholders own 88.55% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.3%
Mount Sinai School Of Medicine, Endowment Arm
37,346,476€5.3m57.1%2.21%
9.96%
Heights Capital Management, Inc.
33,000,000€4.7m754%0.64%
9.79%
James McCullough
32,420,096€4.6m16,800%no data
8.6%
Ruffer LLP
28,500,000€4.1m0%0.06%
8.31%
Polar Capital Holdings Plc
27,520,016€3.9m98.5%0.01%
5.86%
Jefferson River Capital
19,406,044€2.8m134%no data
5.72%
Unicorn Asset Management Ltd.
18,955,777€2.7m1,510%0.35%
5.42%
Pentwater Capital Management LP
17,946,298€2.6m116%0.05%
5.23%
UBS Asset Management AG
17,316,510€2.5m965%no data
4.46%
Harwood Capital LLP
14,777,019€2.1m0%0.16%
4.4%
Christopher Mills
14,561,345€2.1m0%no data
1.21%
NR Holdings Limited
4,001,187€569.4k0%no data
1.21%
DB Capital Venture Partners
4,000,001€569.2k0%100.0%
1.21%
Lombard Odier Asset Management (Europe) Ltd.
4,000,000€569.2k0%0.01%
1%
Pinnacle Associates, Ltd.
3,323,918€473.0k104%no data
0.77%
The Mccullough 2020 Irrevocable Trust
2,554,398€363.5k0%no data
0.61%
National Financial Services LLC, Asset Management Arm
2,022,398€287.8k-0.54%0.01%
0.56%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
1,860,070€264.7k-5.63%no data
0.56%
Julian Baines
1,848,700€263.1k0%no data
0.55%
Oliver Sterling
1,805,236€256.9k0%no data
0.46%
Gilder Gagnon Howe & Co. LLC
1,522,216€216.6k0%no data
0.38%
Stifel Asset Management Corp.
1,255,220€178.6k-11.3%no data
0.34%
Barclays Bank PLC, Wealth and Investment Management Division
1,118,619€159.2k154%no data
0.34%
Levin Capital Strategies, L.P.
1,110,000€158.0k0%0.01%
0.33%
Stockinvest Limited
1,105,000€157.2k5.24%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 09:13
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renalytix Plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Mark MassaroBTIG
David WestenbergGuggenheim Securities, LLC